eIND submission for the PB004 project and further development of PB003G towards Phase 0

Pure Biologics submits an eIND application to the FDA for the start of Phase 0 in the PB004 project and decides on the further development of PB003G toward Phase 0.

News

Inquiries

Pure Biologics optimizes the PB004 plan to obtain relevant clinical data faster

20 September

2022

Pure Biologics optimizes the PB004 plan to obtain relevant clinical data faster

Obtaining the results of phase 0 will allow us to obtain the first information about the effectiveness of the compound in humans faster than by the classic approach, based on phase I and II clinical trials.

PureApta platform – extension of the patent protection

14 September

2022

PureApta platform – extension of the patent protection

Pure Biologics has filed an application for a further extension of patent protection for the PureApta™ platform.

Successful aptamer selection research contract

17 August

2022

Successful aptamer selection research contract

The completed contract opens the way for the possible implementation of the contract guaranteeing the distribution of profits from commercialization of the developed aptamer.

Project PB004 – first administration to animals

9 June

2022

Project PB004 – first administration to animals

On June 7th, 2022, Pure Biologics commenced its first pilot preclinical study in the PB004 project developing a potential drug for the treatment of solid tumors and leukemia.

Pure Biologics with a foreign partner for a new aptamer project

3 June

2022

Pure Biologics with a foreign partner for a new aptamer project

As part of the cooperation aimed at creating a prototype device, Pure Biologics will develop an innovative blood dialysis filter based on aptamer technologies PureApta™, while Relitech will build the first medical device to perform the above procedure.

Zapytanie Ofertowe – 00007/00008_ABM_02/2023

18 December

2023

eIND submission for the PB004 project and further development of PB003G towards Phase 0

Pure Biologics optimizes the PB004 plan to obtain relevant clinical data faster

PureApta platform – extension of the patent protection

Successful aptamer selection research contract

Project PB004 – first administration to animals

Pure Biologics with a foreign partner for a new aptamer project

Zapytanie Ofertowe – 00007/00008_ABM_02/2023

Zapytanie Ofertowe – 00007/00008_ABM_01/2023

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/3/20 10.04.2020